SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (173)5/28/1997 11:57:00 AM
From: NeuroInvestment   of 675
 
While Lipton has made progress in terms of delineating which excitatory amino acid 'markers' may be particularly pathognomic and diagnostic (as a risk factor in individuals under 50), the basic construct of using an NMDA antagonist to ameliorate EAA precipitated excitotoxicity is anything but new. Lipton has a research agreement with NTI, and it was his program with memantine that I referred to in an earlier post. He is a very bright guy with whom I have spoken about his research, and really is responsible for having imported memantine to the US from Germany as a putative neuroprotectant. The new paper does not outline a novel approach to stroke protection, this is post-synaptic receptor inhibition, and the issues continue to be whether Cerestat's demonstrated blocking effect can be accomplished without excessive toxicity, and eventually, if memantine's lower potency means lesser side effects with neuroprotection (which is Lipton's belief). The other strategy would be inhibiting the presynaptic release of EAA's, as is also being avidly pursued. In sum: perhaps homocysteine would prove an avenue to identifying 'at risk' individuals, but thus far it does not point to novel treatment strategies. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News